THERANEXUS: Theranexus publishes its cash position as of June 30, 2022 – 07/12/2022 at 6:00 p.m.

Lyon, France – July 12, 2022 – 6:00 p.m. CEST –

Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases and a pioneer in the development of drug candidates acting on the interaction between neurons and glial cells, today announces its cash position as of June 30, 2022.

Available cash as of June 30, 2022 stood at €11.6 million compared to €12.5 million as of December 31, 2021. The level of cash evolved in line with the company’s forecasts for the first six months of the financial year 2022 and provides the Company with financial visibility for more than 18 months. This healthy financial situation thus validates the choice of the final termination in April 2022 of the equity financing line which had been set up with Iris Capital in January of the same year.

Next financial publication:

September 27, 2022:

Financial results for 1

^er

semester 2022

About Theranexus

Theranexus is an innovative biopharmaceutical company, spun off from the CEA and specializing in the treatment of neurological diseases and a pioneer in the development of drug candidates targeting both neurons and glial cells. Theranexus has a unique platform for the identification and characterization of innovative therapy drug candidates in the field of rare neurological disorders and a first drug candidate in clinical development for Batten disease.

THERANEXUS is listed on the Euronext Growth market in Paris (FR0013286259-ALTHX).

Warning

This press release contains forward-looking statements relating to Theranexus and its business, including its prospects and product development. Theranexus believes that these forward-looking statements are based on reasonable assumptions. However, forward-looking statements are not guarantees of future performance, as they relate to future events and depend on circumstances that may or may not occur in the future, and on various risks and uncertainties, including those described in the company’s universal registration document filed with the AMF on April 28, 2021 under number D. 21-0379, a copy of which is available on the company’s website (www.theranexus.com), and changes in economic conditions, financial markets and markets in which Theranexus is present. The forward-looking statements contained in this press release are also subject to risks unknown to Theranexus or that Theranexus does not consider material at this date. The realization of all or part of these risks could cause the actual results, financial conditions, performances or achievements of Theranexus to differ materially from the results, financial conditions, performances or achievements expressed in these forward-looking statements. Theranexus assumes no responsibility for updating these forward-looking statements.

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com